Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03
ASCO 2026
Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).
The ASCO Post Staff
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
The ASCO Post Staff
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled study of the anti–PD-L1 antibody avelumab in patients with Merkel cell carcinoma and lymph node metastases (Abstract LBA9504).
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a numerically worse prognosis, representing an unmet need for drug development, say researchers (Abstract 1045).
The ASCO Post Staff
Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers.
The ASCO Post Staff
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).
